 |
|
CiprofloxacinUse as a Topical Otic Preparation
Richard E. Brownlee, MD;
Gregory F. Hulka, MD;
Jiri Prazma, MD, PhD;
Harold C. Pillsbury, III, MD
Arch Otolaryngol Head Neck Surg. 1992;118(4):392-396.
Abstract
| |
• Most common topical otic preparations have been shown to cause sensorineural hearing loss and hair-cell damage in experimental animals. Ciprofloxacin is a relatively new fluoroquinolone with excellent activity against Pseudomonas and methicillin-resistant Staphylococcus aureus. Recent studies have shown oral ciprofloxacin to be effective in the treatment of chronic serous otitis media and malignant external otitis. However, this drug has never been used as a topical otic preparation. Thirty-five albino female guinea pigs were used to investigate the ototoxicity of topical ciprofloxacin hydrochloride. Bilateral transbullae drug delivery tubes were placed and auditory brain-stem response thresholds were recorded at 20, 16, 8, and 4 kHz before treatment and 21 days after the completion of treatment. Two groups of guinea pigs were used. In group 1 (positive controls), five guinea pigs had 0.1 mL of neomycin sulfate administered in one ear while the opposite (control) ear received 0.1 mL of 0.9% sodium chloride solution; in group 2, 30 guinea pigs received 0.75% ciprofloxacin ophthalmic solution and 0.9% sodium chloride solution in the control ear. All drugs were given twice a day for 7 consecutive days. All results were evaluated with paired, two-tailed t test and Hotelling's T2 test, and calculation of power was performed on all nonsignificant results. No significant ototoxic reaction was observed; small increases in hearing thresholds occurred at 4 (5.65±8.25 dB [mean±SD]) and 8 kHz (3.70±6.63 dB [mean±SD]) in the ciprofloxacin-treated ears; however, no significant hair-cell loss was seen. Therefore, the hearing loss appears to be due to middle-ear mucosal changes. The planning and analysis of negative experimental trials is discussed, and a model for testing potentially nonototoxic drugs is presented.
(Arch Otolaryngol Head Neck Surg. 1992;118:392-396)
Author Affiliations
From the Division of Otolaryngology—Head and Neck Surgery, University of North Carolina Hospitals, Chapel Hill. Dr Brownlee is now in a fellowship with the Department of Otolaryngology Head and Neck Surgery, University of Oregon Health Sciences Center, Portland.
Footnotes
Accepted for publication August 14, 1991.
Reprints not available.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Safety of Ciprofloxacin and Dexamethasone in the Guinea Pig Middle Ear
Lemke et al.
Arch Otolaryngol Head Neck Surg 2009;135:575-580.
ABSTRACT
| FULL TEXT
Auditory Function After a Prolonged Course of Ciprofloxacin-Dexamethasone Otic Suspension in a Murine Model
Kavanagh et al.
Arch Otolaryngol Head Neck Surg 2009;135:238-241.
ABSTRACT
| FULL TEXT
Treatment of Chronic Suppurative Otitis Media With Topical Tobramycin and Dexamethasone
Alper et al.
Arch Otolaryngol Head Neck Surg 2000;126:165-173.
ABSTRACT
| FULL TEXT
Topical Ciprofloxacin in Long-Lasting Otorrhea
Manestar et al.
Arch Otolaryngol Head Neck Surg 1999;125:236-236.
FULL TEXT
Chronic Otitis Media Treated Topically With Ciprofloxacin or Tobramycin
Milo et al.
Arch Otolaryngol Head Neck Surg 1997;123:1057-1060.
ABSTRACT
Treatment of Chronic Ear Disease: Topical Ciprofloxacin vs Topical Gentamicin
Tutkun et al.
Arch Otolaryngol Head Neck Surg 1995;121:1414-1416.
ABSTRACT
Therapeutic Implications in the Treatment of Aural Pseudomonas Infections Based on In Vitro Susceptibility Patterns
Dohar et al.
Arch Otolaryngol Head Neck Surg 1995;121:1022-1025.
ABSTRACT
|
